RESEARCH & DEVELOPMENT
c-MET Receptor Tyrosine Kinase: A Potential Biomarker for Cancer Therapeutics The c-MET/HGF signaling regulates multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. The c-MET pathway has significant interaction with other signaling pathways. The deregulation of c-MET plays an important role in the formation, growth, maintenance, and invasion of tumors. It is involved in various cancers, including lung, colon, liver and stomach cancer. Many studies on the abnormal signaling of c-MET offer strong reasons to investigate the therapeutic potential of some receptor antagonists. Therefore, more active substances must be selected and integrated effectively into well-designed clinical trials, these include predictive biomarkers such as genetic mutation, amplification and overexpression of immunohistochemical c-MET. The complex interconnection of cell control networks provides new pathways for combining EGFR inhibitors and other targeted drugs. Thus, c-MET can be used as potential biomarkers for cancer therapeutics. 28
P H AR M A F O C U S E U R O PE
ISSUE 01 - 2022
Dhruv Kumar* Senior Associate Professor, School of Health Sciences and Technology, UPES University
Sibi Raj ICMR-SRF Fellow, currently pursuing PhD in Cancer Biology, School of Health Sciences and Technology, UPES University
